Mannkind Corp MNKD
We take great care to ensure that the data presented and summarized in this overview for MANNKIND CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MNKD
View all-
Black Rock Inc. New York, NY22.6MShares$113 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA16.1MShares$80.8 Million0.0% of portfolio
-
State Street Corp Boston, MA9.95MShares$50 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.75MShares$44 Million0.82% of portfolio
-
Nitorum Capital, L.P. New York, NY8.75MShares$44 Million8.23% of portfolio
-
Geode Capital Management, LLC Boston, MA6.37MShares$32.1 Million0.0% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA4.89MShares$24.6 Million0.03% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY4.27MShares$21.5 Million0.02% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.45MShares$17.3 Million0.01% of portfolio
-
Bank Of America Corp Charlotte, NC3.36MShares$16.9 Million0.0% of portfolio
Latest Institutional Activity in MNKD
Top Purchases
Top Sells
About MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Insider Transactions at MNKD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 04
2025
|
Michael Castagna Chief Executive Officer |
SELL
Other acquisition or disposition
|
Direct |
39,500
-1.72%
|
-
|
|
Mar 27
2025
|
Lauren M Sabella EVP Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
16,407
-4.38%
|
$82,035
$5.1 P/Share
|
|
Feb 12
2025
|
Dominic Marasco Pres, Endocrine Business Unit |
BUY
Grant, award, or other acquisition
|
Direct |
252,000
+50.0%
|
-
|
|
Nov 22
2024
|
Steven B. Binder |
SELL
Open market or private sale
|
Direct |
67,536
-5.91%
|
$405,216
$6.89 P/Share
|
|
Nov 22
2024
|
Steven B. Binder |
BUY
Exercise of conversion of derivative security
|
Direct |
67,536
+5.58%
|
$67,536
$1.47 P/Share
|
|
Nov 15
2024
|
Steven B. Binder |
SELL
Open market or private sale
|
Direct |
67,539
-5.91%
|
$405,234
$6.76 P/Share
|
|
Nov 15
2024
|
Steven B. Binder |
BUY
Exercise of conversion of derivative security
|
Direct |
67,539
+5.58%
|
$67,539
$1.47 P/Share
|
|
Nov 06
2024
|
Stuart A Tross Chief People & Workpl Officer |
SELL
Open market or private sale
|
Direct |
55,000
-5.38%
|
$385,000
$7.34 P/Share
|
|
Oct 31
2024
|
Sanjay R Singh EVP Technical Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
17,071
-4.24%
|
$119,497
$7.07 P/Share
|
|
Sep 03
2024
|
Stuart A Tross Chief People & Workpl Officer |
SELL
Open market or private sale
|
Direct |
25,000
-2.39%
|
$150,000
$6.26 P/Share
|
|
Aug 30
2024
|
Stuart A Tross Chief People & Workpl Officer |
SELL
Open market or private sale
|
Direct |
80,000
-3.61%
|
$480,000
$6.33 P/Share
|
|
Aug 29
2024
|
David Thomson EVP Genl Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
5,553
-0.66%
|
$27,765
$5.94 P/Share
|
|
Aug 29
2024
|
Steven B. Binder |
SELL
Open market or private sale
|
Direct |
5,055
-0.47%
|
$25,275
$5.94 P/Share
|
|
Aug 29
2024
|
Michael Castagna Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
85,106
-3.58%
|
$510,636
$6.3 P/Share
|
|
Aug 29
2024
|
Michael Castagna Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
19,000
-0.79%
|
-
|
|
Aug 28
2024
|
Michael Castagna Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
13,894
-0.58%
|
-
|
|
Aug 27
2024
|
David Thomson EVP Genl Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
22,489
-2.62%
|
$112,445
$5.38 P/Share
|
|
Aug 27
2024
|
Steven B. Binder |
SELL
Payment of exercise price or tax liability
|
Direct |
20,779
-1.89%
|
$103,895
$5.38 P/Share
|
|
Aug 27
2024
|
Stuart A Tross Chief People & Workpl Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20,779
-1.81%
|
$103,895
$5.38 P/Share
|
|
Aug 27
2024
|
Michael Castagna Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
56,085
-2.27%
|
$280,425
$5.38 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 2.35M shares |
|---|---|
| Exercise of conversion of derivative security | 135K shares |
| Payment of exercise price or tax liability | 826K shares |
|---|---|
| Open market or private sale | 453K shares |
| Bona fide gift | 32.9K shares |
| Other acquisition or disposition | 92.5K shares |